gms | German Medical Science

63. Jahrestagung der Deutschen Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie e. V. (GMDS)

Deutsche Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie

02. - 06.09.2018, Osnabrück

Exploration of molecular risk modifying factors for adverse drug reactions

Meeting Abstract

  • Maren Kleine - Universität Bielefeld, Bielefeld, Deutschland
  • Alban Shoshi - Universität Bielefeld, Bielefeld, Deutschland
  • Cassandra Königs - Universität Bielefeld, Bielefeld, Deutschland
  • Alex Maier - Universität Bielefeld, Bielefeld, Deutschland
  • Olga Zolotareva - Universität Bielefeld, Bielefeld, Deutschland
  • Ralf Hofestaedt - Department of Bioinformatics and Medical Informatics, Faculty of Technology, Bielefeld University, Bielefeld, Deutschland

Deutsche Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie. 63. Jahrestagung der Deutschen Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie e.V. (GMDS). Osnabrück, 02.-06.09.2018. Düsseldorf: German Medical Science GMS Publishing House; 2018. DocAbstr. 117

doi: 10.3205/18gmds161, urn:nbn:de:0183-18gmds1617

Veröffentlicht: 27. August 2018

© 2018 Kleine et al.
Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). Lizenz-Angaben siehe



Background: The causal analysis of potential adverse drug reactions (ADRs) is verychallenging due to their mechanistic complexity (multiple genes, genetic variations, proteins, and their interaction are relevant) [1]. To investigate the cause of ADRs not only the active agent but also contributory factors in the causal chain have to be studied [2]. Integrative omics help to un derstand disease pathogeneses and drug toxicity at molecular level and to apply predictive models in clinical research and practice [3].

Objective: The problem of identifying effects that are causal to the drug use is the need of qualitative data rather than disease- side effect associations. Adverse reactions include many factors that interact in the causal mechanism. These factors are essential for the effect, but not causal themselves (e.g. genetic susceptibility due to CYP p450 defects). They are categorized as clinical factors (dose responsiveness, time course, comorbidities, etc.) and biological factors (molecular interaction like inhibition of therapeutic targets or key proteins in physiological pathways) [2], [1]. The goal of the tool ADRrisk is to allow the exploration of associated entities on molecular level and thereby develop hypotheses between links and identify risk-modifying factors.

Methods: The associations between therapeutic indications and ADRs are measurable changes of patient phenotype that can be used to study the relationship between disease and drug toxicity [4]. Therefore, we integrated and unified individual case data obtained from pharmacovigilance databases (FDA FAERS, Canadian CVARD and Yellow Card Scheme from the UK [5], [6], [7]) to find significant associations between indication and ADR. We implemented the web application RiskADR to visualize the obtained associations in a network and display the connected molecular information for further analysis. Molecular links are queried from a heterogeneous network integrated in a Neo4j database, that contains the relevant biological entities (e.g. gene, disease, pathway, protein, variant) involved in action of a drug using established databases like Uniprot, Gene Ontology, and Reactome. The database ADReCS-Target, for instance, summarizes information on ADR, gene variant and protein associations obtained from curated literature mining. Using the graph database, disease-ADR associations can be analyzed by determining the shortest path in the network between the node entities. RiskADR is a shinyR web application [8] that incorporates the vis.js javascript library for network visualization and RNeo4j connector.

Results and Discussion: Causation of adverse drug reactions is a complex issue that requires indepth knowledge of clinical aspects as well as knowledge of the underlying molecular processes. The result set contains 174,485 disease-ADR associations obtained by logistic regression models controlling for number ofdrugs, sex and age group. For each association FDR-adjusted p-values and association measures are displayed to filter significant pairs of interest. Applications like RiskADR contribute to systems medicine and helpto mechanistically analyze drug-ADR pairs and are a promising solution to the complex problem of understanding mechanisms of toxicity.

The authors declare that they have no competing interests.

The authors declare that an ethics committee vote is not required.


Edwards RI. Causality Assessment in Pharmacovigilance: Still a Challenge. Drug safety. 2017;40(5):365. DOI: 10.1007/s40264-017-0509-2 Externer Link
Zhou L, Rupa AP. Categorization and association analysis of risk factors for adverse drug events. Eur J Clin Pharmacol. 2018 Apr;74(4):389-404. DOI: 10.1007/s00228-017-2373-5 Externer Link
Karczewski KJ, Snyder MP. Integrative omics for health and disease. Nat Rev Genet. 2018 May;19(5):299-310. DOI: 10.1038/nrg.2018.4 Externer Link
Wang F, et al. Exploring the associations between drug side-effects and therapeutic indications. Journal of biomedical informatics. 2014;51:15. DOI: 10.1016/j.jbi.2014.03.014 Externer Link
U.S. Food and Drug Administration. FDA Adverse Event Reporting System (FAERS). [cited 2019 Apr 29]. Available from: Externer Link
Medicines and Healthcare Products Regulatory Agency. Yellow Card Scheme. [cited 2019 Apr 29]. Available from: Externer Link
Health Canada. Canada Vigilance Adverse Reaction Online Database (CVARD). [cited 2019 Apr 29]. Available from: Externer Link
Chang W, et al. shiny: Web Application Framework for R. R package version Available from: Externer Link
Ferner RE, Aronson JK. EIDOS: a mechanistic classification of adverse drug effects. Drug safety. 2010;33(1):15. DOI: 10.2165/11318910-000000000-00000 Externer Link
Huang LH, et al. ADReCS-Target: Target profiles for aiding drug safety research and application. Nucleic Acids Research. 2018;46. DOI: 10.1093/nar/gkx899 Externer Link